Table 2

Characteristics of cancers in juvenile-onset arthritis

					Prior*
Cancer type	Sex	Race	Arthritis Type	Age at cancer	DMARD	Biologic	Vital status†	Country‡	Arthritis§ duration	Cancer date
Hodgkin's lymphoma	M	White	Enthesitis-related	18	No	No	Alive	CA	2	2005
B-cell lymphocytic leukaemia	F	First Nation	Polyarticular rheumatoid factor negative	9	Yes	No	Deceased	USA	4	2002
Hepatosplenic T-cell NHL	F	White	Systemic	16	Yes	Yes	Deceased	CA	8	2009
Polymorphic post-transplantation lymphoproliferative disease	M	White	Polyarticular rheumatoid factor positive	16	Yes	Yes	Deceased	USA	3	2010
Papillary follicular adenocarcinoma thyroid	F	White	Oligoarticular persistent	13	No	No	Alive	USA	8	2011
Renal cell adenocarcinoma	F	White	Polyarticular rheumatoid factor negative	24	Yes	Yes	Alive	CA	19	2008
Glioma	M	White	Oligoarticular persistent	10	No	No	Alive	CA	5	2008
Primitive neuroectodermal (Ewing) cancer	F	White	Oligoarticular extended	17	Yes	Yes	Deceased	CA	6	2009
Endometrial adenocarcinoma	F	White	Enthesitis-related	30	Yes	Yes	Alive	CA	14	2011

*Prior DMARD=use of disease-modifying antirheumatic agent prior to cancer onset.
†Vital status as of time of cancer registry linkage.
‡CA=Canada.
§Time between arthritis diagnosis and cancer diagnosis.
Prior to the B-cell lymphocytic leukaemia, the patient received MTX for 1 year prior to the hepatosplenic T-cell NHL, the patient was on MTX for 3.6 years, etanercept for 0.1 year, then infliximab for 1.7 years, then anakinra for 1.9 years. Prior to the post-transplant lymphoproliferative disorder, the patient had been on MTX for 1 month, etanercept for 6 months, cyclophosphamide for 1 year 3 months and infliximab for 4 months prior to the transplant, and mycophenolate, tacrolimus, rituximab and cyclophosphamide thereafter. Prior to the renal cell cancer, the patient was on MTX for 6.2 years, then leflunomide for 0.2 years, then etanercept for 4.8 years. Prior to the diagnosis of primitive neuroectodermal (Ewing) cancer, the patient was exposed to MTX for at least 20 months and leflunomide for 3 months, and was prescribed Enbrel but was not compliant.
DMARD, disease-modifying antirheumatic drug; F, female; M, male; MTX, methotrexate; NHL, non-Hodgkin's lymphoma.